Holen Sie sich die Stockscreener-App
2.18
2.35%
0.05
Schlusskurs vom Vortag:
$2.13
Offen:
$2.13
24-Stunden-Volumen:
175.65K
Relative Volume:
0.33
Marktkapitalisierung:
$191.72M
Einnahmen:
$7.05M
Nettoeinkommen (Verlust:
$-30.43M
KGV:
-5.755
EPS:
-0.3788
Netto-Cashflow:
$21.84M
1W Leistung:
+0.93%
1M Leistung:
+22.47%
6M Leistung:
-21.01%
1J Leistung:
+32.93%
1-Tages-Spanne:
$2.1067
$2.18
1-Wochen-Bereich:
$2.00
$2.5398
52-Wochen-Spanne:
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Firmenname
Proqr Therapeutics N V
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie PRQR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.18 | 191.72M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-29 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Herabstufung | Stifel | Buy → Hold |
| 2022-02-01 | Eingeleitet | Raymond James | Strong Buy |
| 2021-05-03 | Eingeleitet | Stifel | Buy |
| 2021-03-25 | Bestätigt | Citigroup | Buy |
| 2020-11-03 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-12-19 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-11-15 | Eingeleitet | Citigroup | Buy |
| 2018-09-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-09-26 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-06-20 | Eingeleitet | Chardan Capital Markets | Neutral |
| 2014-10-15 | Eingeleitet | Deutsche Bank | Buy |
| 2014-10-13 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten
Bank of America Corp DE Boosts Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected - simplywall.st
Equities Analysts Offer Predictions for PRQR FY2026 Earnings - MarketBeat
Research Analysts Set Expectations for PRQR FY2026 Earnings - Defense World
Jane Street Group LLC Buys Shares of 11,400 ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Analysts Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $8.00 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Shares Sold by Two Sigma Advisers LP - Defense World
Two Sigma Investments LP Has $1.02 Million Stake in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
Squarepoint Ops LLC Grows Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Two Sigma Investments LP Buys 320,614 Shares of ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of “Buy” by Analysts - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Sees Significant Increase in Short Interest - MarketBeat
ProQR Shareholders Approve Key Resolutions at Annual Meeting - TipRanks
ProQR Therapeutics (NASDAQ:PRQR) Shares Purchased by Northern Trust Corp - MarketBeat
Millennium Management LLC Grows Stock Position in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
BNP Paribas Financial Markets Buys 15,900 Shares of ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Northern Trust Corp Has $1.11 Million Stock Holdings in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Woodline Partners LP Invests $9.43 Million in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
Here's Why ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO May Deserve A Raise - simplywall.st
Millennium Management LLC Buys 2,683,351 Shares of ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Point72 Asset Management L.P. Buys New Position in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year - Investing.com Canada
Cantor Fitzgerald Issues Negative Forecast for PRQR Earnings - MarketBeat
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes Position in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Oppenheimer Has Lowered Expectations for ProQR Therapeutics (NASDAQ:PRQR) Stock Price - Defense World
Research Analysts Issue Forecasts for PRQR FY2025 Earnings - Defense World
ProQR (PRQR) Price Target Cut by Oppenheimer Amid Clinical Updates | PRQR Stock News - GuruFocus
DAFNA Capital Management LLC Buys 661,979 Shares of ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | - GuruFocus
Oppenheimer Adjusts ProQR Therapeutics N.V Price Target to $9 From $15, Maintains Outperform Rating - marketscreener.com
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences - GlobeNewswire
Raymond James Financial Inc. Invests $260,000 in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of “Buy” from Analysts - Defense World
ProQR: Q1 Earnings Snapshot - News-Times
1,181,413 Shares in ProQR Therapeutics (NASDAQ:PRQR) Acquired by ArrowMark Colorado Holdings LLC - MarketBeat
New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR) - simplywall.st
ProQR Therapeutics NV earnings missed, revenue topped estimates - Investing.com Australia
ProQR Therapeutics NV earnings missed, revenue topped estimates By Investing.com - Investing.com Nigeria
ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Finanzdaten der Proqr Therapeutics N V-Aktie (PRQR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):